Page last updated: 2024-10-21

2-amino-5-phosphonovalerate and Insulin Coma

2-amino-5-phosphonovalerate has been researched along with Insulin Coma in 1 studies

2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.

Insulin Coma: Severe HYPOGLYCEMIA induced by a large dose of exogenous INSULIN resulting in a COMA or profound state of unconsciousness from which the individual cannot be aroused.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
NellgÄrd, B1
Wieloch, T1

Other Studies

1 other study available for 2-amino-5-phosphonovalerate and Insulin Coma

ArticleYear
Cerebral protection by AMPA- and NMDA-receptor antagonists administered after severe insulin-induced hypoglycemia.
    Experimental brain research, 1992, Volume: 92, Issue:2

    Topics: 2-Amino-5-phosphonovalerate; Animals; Blood Pressure; Brain Ischemia; Cell Death; Dizocilpine Maleat

1992